Partnership value grows 16% year-over-year, while clinical activity jumps 50%. A sampling of recent reports shows just how much immuno-oncology continues to grow. Behind the sunny forecasts is the expectation of numerous new treatments reaching market, following a significant increase in clinical activity. It is necessary to sustain the momentum generated by biopharmas through their immuno-oncology collaborations . . .
![New research suggest ketogenic diets may cause an increased risk of Type 2 diabetes in the early stage of the diet. [United States Air Force]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug9_2018_KirtlandAirForceBase_KetogenicDiet_SalmonButterOliveOilCoconutSteak1801911782-80x60.jpg "Ketogenic Diet Alters Gut Microbiome Leading to Reduced Levels of Proinflammatory T Cells")
